The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

Early feasibility data from two studies of valve replacement presented at TCT 2021 show promise for novel transcatheter devices for mitral and tricuspid regurgitation. The Intrepid (Medtronic) ...

An initial foray into the ‘final frontier’ of percutaneous valve procedures—tricuspid valve replacement—suggests that a currently available pulmonary valve can feasibly be implanted in the tricuspid ...

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed ... Images in Clinical Medicine ... 4,24–26; studies show that patients who received a permanent ...

While minimally invasive repair devices have shown progress in stemming leaks of the heart’s notoriously tricky tricuspid valve, Edwards Lifesciences aims to show that replacing the valve ...

In the midst of transformative transcatheter approaches to repair diseased aortic and mitral valves, the tricuspid valve has been overshadowed, according to Michael E. Bowdish, MD, vice chair of ...

Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.

If a person’s heart valves become damaged, they may benefit from having heart valve replacement surgery. Doctors may assess a person's suitability for the surgery. Learn more here.

NEW ORLEANS — Treatment of severe tricuspid regurgitation with transcatheter repair was safe, reduced severity of tricuspid regurgitation and led to improvements in quality of life at 1 year ...

Source Reference: Hahn RT, et al "Transcatheter valve replacement in severe tricuspid regurgitation" N Engl J Med 2024; DOI: 10.1056/NEJMoa2401918. Share on Facebook. Opens in a new tab or window ...